Cryoablation

Aetna covers cryoablation for adrenal metastases and renal masses ≤4 cm (renal limited to confirmed/suspected RCC in patients who are high‑risk surgical candidates, have GFR ≤60 ml/min/m2, or have a solitary kidney), for cervical intraepithelial neoplasia, for prostate cancer as primary or salvage therapy for localized disease (T1–T3), and for atrial fibrillation (e.g., cryoballoon pulmonary vein isolation) when AF is drug‑resistant, drug‑intolerant, or the patient declines long‑term drug therapy. Cryoablation is considered experimental/investigational (and not covered) for prostate benign prostatic hypertrophy, breast carcinoma/fibroadenoma and numerous other indications (including spray cryotherapy for subglottic/cervical tracheal stenosis and endoluminal cryoablation for varicose veins).

"Osteoid osteoma: although cryoablation is effective, RFA is generally considered the preferred/gold standard technique in many reviews; cryoablation used particularly where nerve preservation, visu..."